The discovery in 1982 1 that Helicobacter pylori can colonize the human stomach, leading to chronic gastritis, resulted in a dramatic increase in understanding of the pathophysiology of acid-related diseases. It is now generally accepted that the classic dictum 'no acid, no ulcer' should be replaced by 'no H. pylori, no ulcer'. 2 As a result, national and international management guidelines now recommend that all patients with peptic ulcer and proven H. pylori infection should receive H. pylori eradication therapy. 3 -7 The most effective H. pylori eradication regimens are those that consist of a proton pump inhibitor (PPI), such as omeprazole, plus two antimicrobial agents. 8 In large clinical trials, such regimens have been shown to produce eradication rates of approximately 85 -95%, which are associated with ulcer healing in the majority of patients. 9 -12 By contrast, triple regimens consisting of an H 2 -receptor antagonist and two antimicrobials appear to be less effective, producing eradication rates of ~60 -70%. 8,13 As a result, PPI-based regimens are now accepted as the standard treatment
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The discovery in 1982 1 that Helicobacter pylori can colonize the human stomach, leading to chronic gastritis, resulted in a dramatic increase in understanding of the pathophysiology of acid-related diseases. It is now generally accepted that the classic dictum 'no acid, no ulcer' should be replaced by 'no H. pylori, no ulcer'. 2 As a result, national and international management guidelines now recommend that all patients with peptic ulcer and proven H. pylori infection should receive H. pylori eradication therapy. 3 -7 The most effective H. pylori eradication regimens are those that consist of a proton pump inhibitor (PPI), such as omeprazole, plus two antimicrobial agents. 8 In large clinical trials, such regimens have been shown to produce eradication rates of approximately 85 -95%, which are associated with ulcer healing in the majority of patients. 9 -12 By contrast, triple regimens consisting of an H 2 -receptor antagonist and two antimicrobials appear to be less effective, producing eradication rates of ~60 -70%. 8 An open, randomized trial was performed to compare the efficacy of three Helicobacter pylori eradication regimens in children with peptic ulcer disease. A total of 106 children (5 -15 years) were treated for 1 week with metronidazole, 30 -40 mg/kg per day depending on age, amoxycillin, 750 mg/day, and one of three anti-secretory agents: proprietary omeprazole, 20 -40 mg/day depending on age; generic omeprazole, 20 -40 mg/day; or ranitidine, 150 mg twice daily. The H. pylori eradication rate was significantly higher in patients receiving proprietary omeprazole (88.9%) than in those receiving generic omeprazole (80.0%) or ranitidine (74.3%), and this was associated with a trend towards faster ulcer healing. It is concluded that triple therapy consisting of an anti-secretory agent and two antimicrobials produces effective eradication of H. pylori and ulcer healing in children with peptic ulcer disease, and that proprietary omeprazole is more effective than both ranitidine and the generic formulation used in this study.
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for H. pylori infection, 14 and have been consistently recommended in management guidelines. 4, 5, 7 The inclusion of a PPI appears to be critical for the success of triple therapy eradication regimens. In the MACH2 Study, for example, triple therapy with omeprazole and clarithromycin plus either amoxycillin or metronidazole achieved eradication rates of 87 -94%, compared with 26% for the combination of clarithromycin and amoxycillin alone and 69% for clarithromycin and metronidazole alone. 10 Furthermore, omeprazole appeared to reduce the impact of primary antibiotic resistance and to decrease the risk of secondary resistance, compared with regimens containing two antibiotics only.
Proton pump inhibitors and H 2 -receptor antagonists are increasingly becoming available in generic form, and this raises questions as to the therapeutic equivalence of different preparations. Hence, a randomized trial was performed to compare the efficacy of triple therapy eradication regimens containing either proprietary or generic omeprazole formulations, or ranitidine, in children with peptic ulcer and H. pylori infection.
Patients and methods

PATIENTS
Patients were eligible for inclusion in the study if they were aged between 5 years and 15 years and had endoscopically confirmed duodenal ulcer (defined as at least one lesion of 5 mm in diameter) with H. pylori infection and chronic gastritis. Patients were excluded if they had upper gastrointestinal malignancy or other chronic diseases, or if they had been treated with PPIs, H 2 -receptor antagonists, or bismuth compounds during the 4 weeks prior to entry to the study. Other exclusion criteria were treatment with aspirin or other non-steroidal anti-inflammatory drugs, known allergy to study medication, or suspected poor compliance with study treatment. Written informed consent was obtained from all patients and their parents or guardians before entry to the study.
This study was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki, and was approved by the local ethics committee.
STUDY DESIGN
The study was an open, randomized trial carried out at a single centre. Eligible patients were randomized to receive one of three treatments: proprietary omeprazole (Losec ® , AstraZeneca, UK), 20 mg/day in children aged 5 -11 years or 40 mg/day in children aged 12 -15 years; generic omeprazole (Omez ® , Dr Reddy's Laboratories Ltd, India), 20 mg/day in children aged 5 -11 years or 40 mg/day in children aged 12 -15 years; ranitidine (Raniberl ® , Berlin-Chemie AG, Germany), 150 mg twice daily, for 1 week. In addition, all patients received amoxycillin, 750 mg/day, and metronidazole, 30 mg/kg per day in patients aged 5 -11 years or 40 mg/kg per day in patients aged 12 -15 years.
Dyspeptic symptoms (epigastric pain or discomfort, heartburn, nausea, vomiting, belching) were recorded by a structured interview at the beginning and end of the treatment period, and 6 weeks after the end of treatment. Symptoms were recorded on a fourpoint scale (0, none; 1, mild; 2, moderate; 3, severe). Adverse events were recorded by the investigators after 1 week and 6 weeks.
Before entering the trial and 1 week and 6 weeks after cessation of the study medication, an upper gastrointestinal endoscopy was performed, and three biopsies were taken from the antrum and two from the corpus. Ulcer healing was PL Shcherbakov, VA Filin, IA Volkov et al. H. pylori eradication in children with peptic ulcers confirmed by endoscopy after 7 days, and anti-secretory treatment was continued for a further 3 days if ulcer healing had not occurred by this time. A criterion of ulcer healing was scar formation. The criteria of ulcer non-healing were perifocal hyperaemia and active ulcer with white coat. One antrum and one corpus biopsy were each analysed by a rapid urease test (De-nol ® test, Yamanouchi Europe BV, The Netherlands). Two antrum biopsies (before treatment) and one antral and one corpus biopsy (after 6 weeks) were stored in tubes containing formalin. These biopsies were stained with the Giemsa method for assessment of H. pylori and with haematoxylin and eosin for scoring of the severity of gastritis. 15 Patients were considered to be infected with H. pylori if a positive rapid urease test was confirmed by histology. Cure of the infection was assumed if both the rapid urease test and histology gave negative results at the final examination.
The primary objective of the study was the cure of H. pylori infection. Two approaches to the analysis of efficacy were used. The intention-to-treat analysis included all patients. Patients with missing data at the final follow-up visit were considered to be not cured (H. pylori) or not healed (duodenal ulcer). The per-protocol analysis included all patients without major protocol violation. Drop-outs due to adverse events were included in the per-protocol analysis for ulcer healing as not healed. For the analysis of H. pylori cure rates, however, these patients were excluded. Secondary objectives were healing of ulcer, relief from gastrointestinal symptoms, improvement of gastritis, and safety as assessed by adverse-event recording.
STATISTICAL ANALYSIS
Sample size estimation was based on the assumption that with a total of 50 protocolcorrect patients in the study and a 90% cure of infection, the lower 95% confidence limit of the H. pylori cure rate would be 80%. The primary objective of the study was improvement in H. pylori cure rate. The point estimate was determined according to the binomial distribution and the 95% confidence limits were calculated according to standard normal approximation of the binomial distribution. Differences in eradication rates and ulcer healing rates between the groups were analysed by χ 2 -test. Changes in symptom scores were analysed by Wilcoxon's rank sum test. The mean ulcer sizes before enrolment into the study were compared using an unpaired t-test. Significance was set at P < 0.05.
The most common adverse events occurring during treatment judged by the investigator to be, possibly, probably or certainly related to treatment (according to the total number of patients experiencing them) were tabulated by treatment group. Adverse events experienced by at least five patients in total were included in this analysis.
Results
A total of 106 children took part in the study. There were no significant differences between the groups in demographic and clinical characteristics at baseline (Table 1) .
Overall, H. pylori was eradicated in 86 patients (81.1%). The eradication rate in the group receiving proprietary omeprazole was significantly higher than in the other groups (P < 0.05; Table 2 ). Similarly, ulcer healing rates at the end of treatment tended to be higher in patients receiving proprietary omeprazole than in those receiving generic omeprazole, although the difference between the groups was not significant (P = 0.14). By 6 weeks after the end of treatment, healing rates were 100% in both groups. Two ranitidine-treated patients experienced PL Shcherbakov, VA Filin, IA Volkov et al. H. pylori eradication in children with peptic ulcers relapse 4 weeks after the start of treatment, resulting in a 6-week healing rate of 94.3% ( Table 2) .
Endoscopic examination of the healed ulcers revealed marked differences between the groups. In patients receiving proprietary omeprazole or ranitidine, the scars were tender and without deformations (Fig. 1) . By contrast, in patients receiving generic omeprazole the scars were rough, with fold convergence and deformations in the duodenal bulb (Figs 2 and 3) .
At the start of the study, all patients had epigastric pain and other dyspeptic symptoms. All three treatments produced rapid symptom relief during the first week (Fig. 4 ); however, as described above, two children in the ranitidine group experienced ulcer relapses, resulting in recurrence of epigastric pain, heartburn and nausea.
All three treatments were well tolerated. Only one child in the proprietary omeprazole group, two children in the 
Discussion
The results of this open, randomized study show that a regimen containing proprietary omeprazole, amoxycillin and metronidazole is significantly more effective in eradicating H. pylori than regimens based on a generic omeprazole preparation or ranitidine. The eradication rate achieved with this regimen was higher than that achieved with the same drug combination in the MACH1 Study. 9 This may be related to differences in the antimicrobial doses used in the two trials. The eradication rate achieved with ranitidinebased triple therapy was comparable to those reported in previous trials. 8, 13 The proprietary formulation of omeprazole also appeared to produce faster ulcer healing than the generic preparation, as ulcer healing had been achieved by 7 days in only 82.9% of patients receiving generic omeprazole, compared with all patients receiving the proprietary formulation. These differences in eradication and healing rates may reflect pharmacokinetic characteristics of the generic formulation used in this study. Marked within-subject and between-subject variability in bioavailability and pharmacokinetic profiles has been reported in bioequivalence studies with generic omeprazole preparations. 16 The character of endoscopic reparation of ulcer was different in patients receiving proprietary and generic omeprazole. In patients receiving proprietary omeprazole or ranitidine, the scars were tender and with no deformations in the duodenal bulb. In patients receiving generic omeprazole, however, the scars were rough, with fold convergence and deformations in the duodenal bulb. Duodenum ulcer is a chronic disease with rapid recurrence. It is preferable, therefore, particularly in children, to have the tender scar because rough scars with fold convergence result in deformations of the duodenal bulb and these would subsequently require surgery.
Relatively few studies have evaluated different H. pylori eradication regimens in children. Eradication rates of 75 -88% have been reported with regimens consisting of a PPI, clarithromycin and a second antimicrobial agent. 17 Our experience with proprietary omeprazole thus compares favourably with previous studies. As in adults, eradication of H. pylori in children is associated with long-term healing of peptic ulcer. 17 -19 In conclusion, this study has shown that triple therapy with proprietary omeprazole, 
